AR021596A1 - Compuestos que inhiben la procolageno c-proteinasa. - Google Patents

Compuestos que inhiben la procolageno c-proteinasa.

Info

Publication number
AR021596A1
AR021596A1 ARP990106263A ARP990106263A AR021596A1 AR 021596 A1 AR021596 A1 AR 021596A1 AR P990106263 A ARP990106263 A AR P990106263A AR P990106263 A ARP990106263 A AR P990106263A AR 021596 A1 AR021596 A1 AR 021596A1
Authority
AR
Argentina
Prior art keywords
compounds
proteinase
procolageno
inhibit
methods
Prior art date
Application number
ARP990106263A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR021596A1 publication Critical patent/AR021596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Compuestos de la Formula 1 en donde R1 - R7, A, Z y n son como se describieron en la descripcion, que son inhibidores de la procolágeno C-proteinasa,composiciones farmacéuticas que los contienen, métodos para su uso y métodos para su preparacion.
ARP990106263A 1998-12-10 1999-12-09 Compuestos que inhiben la procolageno c-proteinasa. AR021596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11166198P 1998-12-10 1998-12-10

Publications (1)

Publication Number Publication Date
AR021596A1 true AR021596A1 (es) 2002-07-31

Family

ID=22339762

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106263A AR021596A1 (es) 1998-12-10 1999-12-09 Compuestos que inhiben la procolageno c-proteinasa.

Country Status (12)

Country Link
US (2) US6426402B1 (es)
EP (1) EP1137661A1 (es)
JP (1) JP2002531576A (es)
KR (1) KR20010080709A (es)
CN (1) CN1330661A (es)
AR (1) AR021596A1 (es)
AU (1) AU772575B2 (es)
BR (1) BR9916004A (es)
CA (1) CA2352740A1 (es)
TR (1) TR200101663T2 (es)
WO (1) WO2000034313A1 (es)
ZA (1) ZA200104672B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
JP2005516054A (ja) * 2002-01-29 2005-06-02 ワイス コネキシンヘミチャンネルを調節する組成物及びその方法
FR2840897B1 (fr) 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
US20040213758A1 (en) * 2003-04-23 2004-10-28 Rimon Therapeutics Ltd. Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases
US20070160655A1 (en) * 2003-04-23 2007-07-12 Sefton Michael V Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
KR100629712B1 (ko) * 2003-08-26 2006-09-29 (주)아모레퍼시픽 항노화 효과를 나타내는 히드록삼산 유도체 및 이의제조방법
CA2937005A1 (en) 2005-03-22 2006-09-28 President And Fellows Of Harvard College Treatment of protein degradation disorders
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
AU2007214458C1 (en) * 2006-02-14 2012-12-06 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
JP5497431B2 (ja) 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
WO2009105774A2 (en) * 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
CN102171185A (zh) 2008-08-01 2011-08-31 拜奥西尼斯医药股份有限公司 甲硫氨酸类似物及其使用方法
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
JP2017507915A (ja) * 2014-01-10 2017-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ヒドロキシホルムアミド誘導体およびそれらの使用
WO2017006296A1 (en) * 2015-07-09 2017-01-12 Glaxosmithkline Intellectual Property (No.2) Limited N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors
US9813673B2 (en) 2016-01-20 2017-11-07 Gerard Dirk Smits Holographic video capture and telepresence system
CN115197102B (zh) * 2021-04-12 2023-10-20 山东大学 类肽异羟肟酸类恶性疟原虫氨肽酶抑制剂及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54551B1 (en) 1982-01-22 1989-11-22 Ici Plc Amide derivatives
JPH01146896A (ja) * 1987-12-04 1989-06-08 Fuji Yakuhin Kogyo Kk 新規なペプチジルヒドロキサム酸誘導体
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
CA2170766A1 (en) * 1993-11-05 1995-05-11 Gary Louis Bolton Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
JPH0925293A (ja) * 1995-02-14 1997-01-28 Teijin Ltd ヒスチジル−ヒドロキサム酸誘導体
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
JPH08311096A (ja) 1995-05-18 1996-11-26 Teijin Ltd Ｍｍｐ阻害作用を有する新規なヒスチジル−ヒドロキサム酸誘導体
JPH11511137A (ja) 1995-08-08 1999-09-28 ファイブロゲン，インコーポレーテッド コラーゲンの過剰生産に関係した疾患を治療するためのｃ−プロテイナーゼ阻害剤
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
WO1997049679A1 (fr) 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Derives d'aryle (sulfure, oxyde sulfonique et sulfone) et medicaments les contenant en tant que principe actif
WO1998015525A1 (fr) 1996-10-07 1998-04-16 Sumitomo Pharmaceuticals Co., Ltd. Acides hydroxamiques
AR016751A1 (es) 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
AU7751598A (en) * 1997-06-11 1998-12-30 Carlton And United Breweries Limited A container for separately storing flowable materials but allowing mixing of materials when required

Also Published As

Publication number Publication date
CN1330661A (zh) 2002-01-09
AU2537500A (en) 2000-06-26
ZA200104672B (en) 2002-09-09
TR200101663T2 (tr) 2001-11-21
WO2000034313A1 (en) 2000-06-15
US20020169133A1 (en) 2002-11-14
BR9916004A (pt) 2001-10-02
KR20010080709A (ko) 2001-08-22
CA2352740A1 (en) 2000-06-15
US6951918B2 (en) 2005-10-04
JP2002531576A (ja) 2002-09-24
EP1137661A1 (en) 2001-10-04
AU772575B2 (en) 2004-04-29
US6426402B1 (en) 2002-07-30

Similar Documents

Publication Publication Date Title
AR021596A1 (es) Compuestos que inhiben la procolageno c-proteinasa.
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
GT199900040A (es) Biciclo [2.2.1] heptanos y compuestos relacionados.
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
AR028948A1 (es) Compuestos novedosos
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
MX9100628A (es) Compuestos peptidomimeticos de borolisina y procedimiento para su preparacion.
BR9714377B1 (pt) compostos derivados de 3-tiocarbamoilpirazol, seus processos de preparaÇço, uso, assim como pesticidas contendo referidos compostos.
CL2004001128A1 (es) Compuestos derivados de halogenopirimidinas aril eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida.
ES2094380T3 (es) Nuevos pirazolilpirazoles sustituidos, procedimientos para su preparacion, asi como compuestos intermedios, y su uso como herbicidas.
SV2004001432A (es) 2-tio-3,5-diciano-4-4fenil-6-aminopiridinas substituidas y su uso ref. lea 35 640-sv
UY28342A1 (es) Nuevos compuestos
AR024138A1 (es) Inhibidores de la proliferacion celular
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR028443A1 (es) Nuevos compuestos derivados de piperazina y piperidina, metodo para su preparacion, composiciones farmaceuticas que los contienen y preparacion de las mismas y uso de dichos compuestos
SV1999000006A (es) Nuevas sulfonamidas naftil- y anilido-substituidas ref. lea 32809-sv
AR008781A1 (es) Compuestos de furano nitrona
AR001813A1 (es) Derivados de cromona procedimiento para prepararlos y las composiciones farmacéutica que los contienen
AR028947A1 (es) Compuestos novedosos
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
GT199900113A (es) Inhibidores de las fkbp.
SV1997000010A (es) Nuevas heteroariloxazolidinonas ref. lea 31535-sv
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES2166026T3 (es) Derivados de 1,2,3-benzotiadiazol y su uso como microbicidas.
AR006675A1 (es) 4-benzoilisotiazoles herbicidas, procedimiento para obtenerlas, las composiciones herbicidas que las contienen y el procedimiento de aplicacionde dichos compuestos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure